Radio and PodcastRadio and PodcastLive Radio & Podcasts
Daraxonrasib, Zanidatamab, and CNS Lymphoma Updates artwork
Science & Medicine

Daraxonrasib, Zanidatamab, and CNS Lymphoma Updates

OncoPharm by OncoPharmPod

Aug 27, 202600:20:26Science & Medicine

This week's pod has everything: 1. DDI information and dosing for daraxonrasib, now FDA approved and commercially available for pancreatic cancer 2. A new standard of care (?) in HER(+) gastric cancers, and more nuance o...

Related Episodes

Continue listening to more episodes from OncoPharm.

Lirafugratinib + LITESPARK011

Oct 1, 2026 - 00:15:34

This week's pod offers a brief review of FGFR inhibitors for cholangiocarcinoma in repsonse to the FDA ap...

PI3K Pathway Hyperglycemia

Sep 24, 2026 - 00:10:07

Drugs that inhibit signaling via the PI3K pathway (e.g. alpelisib, capivasertib) can cause hyperglycemia....

Paradigm and Daraxonrasib in NSCLC

Sep 3, 2026 - 00:14:31

PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs....

Iberdomide

Aug 20, 2026 - 00:15:37

CELMoDs are here, but are they here to stay? CELMoD/IMiD review article: Download the Oncology Learning C...